The effects of liraglutide in mice with diet-induced obesity studied by metabolomics

Show simple item record
dc.contributor.authorBugáňová, Martina
dc.contributor.authorPelantová, Helena
dc.contributor.authorHolubová, Martina
dc.contributor.authorŠedivá, Blanka
dc.contributor.authorMaletínská, Lenka
dc.contributor.authorŽelezná, Blanka
dc.contributor.authorKuneš, Jaroslav
dc.contributor.authorKačer, Petr
dc.contributor.authorKuzma, Marek
dc.contributor.authorHaluzík, Martin
dc.date.accessioned2018-02-21T11:35:18Z
dc.date.available2018-02-21T11:35:18Z
dc.date.issued2017
dc.description.abstract-translatedLiraglutide is the glucagon-like peptide-1 receptor agonist widely used for the treatment of type 2 diabetes mellitus. Recently, it has been demonstrated to decrease cardiovascular morbidity and mortality in patients with type 2 diabetes and high cardiovascular risk. Although the major modes of liraglutide action are well-known, its detailed action at the metabolic level has not been studied. To this end, we explored the effect of 2-week liraglutide treatment in C57BL/6 male mice with obesity and diabetes induced by 13 weeks of high-fat diet using NMR spectroscopy to capture the changes in urine metabolic profile induced by the therapy. The liraglutide treatment decreased body and fat pads weight along with blood glucose and triglyceride levels. NMR spectroscopy identified 11 metabolites significantly affected by liraglutide treatment as compared to high-fat diet-fed control group. These metabolites included ones involved in nicotinamide adenine dinucleotide metabolism, β-oxidation of fatty acids and microbiome changes. Although majority of the metabolites changed after liraglutide treatment were similar as the ones previously identified after vildagliptin administration in a similar mouse model, the changes in creatinine, taurine and trigonelline were specific for liraglutide administration. The significance of these changes and its possible use in the personalization of antidiabetic therapy in humans requires further research.en
dc.format10 s.cs
dc.format.mimetypeapplication/pdf
dc.identifier.citationBUGÁŇOVÁ, M., PELANTOVÁ, H., HOLUBOVÁ, M., ŠEDIVÁ, B., MALETÍNSKÁ, L., ŽELEZNÁ, B., KUNEŠ, J., KAČER, P., KUZMA, M., HALUZÍK, M. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics. Journal of endocrinology, 2017, roč. 233, č. 1, s. 93-104. ISSN 0022-0795.en
dc.identifier.doi10.1530/JOE-16-0478
dc.identifier.issn0022-0795
dc.identifier.obd43918306
dc.identifier.urihttp://hdl.handle.net/11025/29185
dc.language.isoenen
dc.publisherBioScientificaen
dc.rightsPlný text není přístupný.cs
dc.rights© BioScientificaen
dc.rights.accessclosedAccessen
dc.subjectNMR metabolomikacs
dc.subjectliraglutidcs
dc.subjectobezitacs
dc.subjectdiabetes mellitus 2. typucs
dc.subjectmočcs
dc.subject.translatedNMR metabolomicsen
dc.subject.translatedliraglutideen
dc.subject.translatedmouse urineen
dc.subject.translatedobesityen
dc.subject.translatedtype 2 diabetes mellitusen
dc.titleThe effects of liraglutide in mice with diet-induced obesity studied by metabolomicsen
dc.typečlánekcs
dc.typearticleen
dc.type.statusPeer-revieweden
dc.type.versionpublishedVersionen

Files

Collections

OBD
 Articles (KMA)
 OPEN License Selector